Search clinical trials for: Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative

Total 61 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
The University of Hong Kong
Centers for Disease Control and Prevention

Active, not recruiting

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PIVOT)

Influenza, Human

China
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
British Columbia Centre for Disease Control
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Active, not recruiting

TITRE III: Influenza B Immunogenicity Investigation

Influenza

Canada
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
The University of Hong Kong
Centers for Disease Control and Prevention; Hospital Authority, Hong Kong

Active, not recruiting

Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong (RETAIN)

Influenza, Human

China
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza

United Kingdom
University of Sao Paulo General Hospital

Completed

Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

Sjogren's Syndrome | Systemic Lupus

Brazil
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Influence of Chronic CMV Infection on Influenza Vaccine Responses (SLVP025)

Influenza | Cytomegalovirus Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Influenza

Germany
Tel-Aviv Sourasky Medical Center

Unknown

Influenza Vaccination in Fibromyalgia Patients

Fibromyalgia Syndrome

Israel
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Influenza

United States
GlaxoSmithKline

Completed

Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over

Influenza

Norway, Estonia, Denmark
Liquidia Technologies, Inc.
Children's Hospital Medical Center, Cincinnati; Accelovance

Completed

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 (LIfT)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

Influenza

United States
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Influenza

United States, United Kingdom
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
PharmaJet, Inc.

Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Influenza Prophylaxis

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
British Columbia Centre for Disease Control

Unknown

TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost (TITRE IIB)

Influenza

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

Influenza

China
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

Influenza

Italy
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States

3

Subscribe